InterMune, Inc. ITMN
today announced that Health Canada has approved Esbriet® (pirfenidone) for the
treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in adult
patients. IPF is a progressive and uniformly fatal disease that affects
approximately 5,000 to 8,000 Canadians, is characterized by scarring of lung
tissue, and has a similar short life expectancy to that of many forms of
cancer, including lung, colorectal and breast cancers. Health Canada
designated Esbriet for Priority Review and completed the accelerated review
according to target guidelines of 180 days.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in